{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:49:25Z","timestamp":1791877765492,"version":"4.3.4"},"reference-count":153,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Like all fields of medicine, Infectious Diseases is rife with dogma that underpins much clinical practice. In this study, we discuss 2 specific examples of historical practice that have been overturned recently by numerous prospective studies: traditional durations of antimicrobial therapy and the necessity of intravenous (IV)-only therapy for specific infectious syndromes. These dogmas are based on uncontrolled case series from &amp;gt;50 years ago, amplified by the opinions of eminent experts. In contrast, more than 120 modern, randomized controlled trials have established that shorter durations of therapy are equally effective for many infections. Furthermore, 21 concordant randomized controlled trials have demonstrated that oral antibiotic therapy is at least as effective as IV-only therapy for osteomyelitis, bacteremia, and endocarditis. Nevertheless, practitioners in many clinical settings remain refractory to adopting these changes. It is time for Infectious Diseases to move beyond its history of eminent opinion-based medicine and truly into the era of evidenced-based medicine.<\/jats:p>","DOI":"10.1093\/ofid\/ofac706","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T18:11:42Z","timestamp":1672337502000},"source":"Crossref","is-referenced-by-count":77,"title":["Can the Future of ID Escape the Inertial Dogma of Its Past? The Exemplars of Shorter Is Better and Oral Is the New IV"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-2264","authenticated-orcid":false,"given":"Kusha","family":"Davar","sequence":"first","affiliation":[{"name":"Los Angeles County + University of Southern California (LAC+USC) Medical Center , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Clark","sequence":"additional","affiliation":[{"name":"Los Angeles County + University of Southern California (LAC+USC) Medical Center , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Centor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Birmingham Veterans Affairs (VA) Medical Center , Birmingham, Alabama, Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dominguez","sequence":"additional","affiliation":[{"name":"Los Angeles County + University of Southern California (LAC+USC) Medical Center , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Ghanem","sequence":"additional","affiliation":[{"name":"King Abdulaziz Medical City , Jeddah , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-4239","authenticated-orcid":false,"given":"Todd C","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0783-0624","authenticated-orcid":false,"given":"Emily G","family":"McDonald","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, McGill University , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C","family":"Phillips","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts , USA"},{"name":"Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parham","family":"Sendi","sequence":"additional","affiliation":[{"name":"Institute for Infectious Diseases, University of Bern , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Spellberg","sequence":"additional","affiliation":[{"name":"Los Angeles County + University of Southern California (LAC+USC) Medical Center , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"2023012011495749600_ofac706-B1","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab490","article-title":"Opinion-based recommendations: beware the tyranny of experts","volume":"8","author":"Spellberg","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023012011495749600_ofac706-B2","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.7326\/M21-3034","article-title":"The future of medical guidelines\u2014standardizing clinical care with the humility of uncertainty","volume":"174","author":"Spellberg","year":"2021","journal-title":"Ann Intern Med"},{"key":"2023012011495749600_ofac706-B3","volume-title":"Rising Plague: The Global Threat from Deadly Bacteria and Our Dwindling Arsenal to Fight Them","author":"Spellberg","year":"2009"},{"key":"2023012011495749600_ofac706-B4","volume-title":"Encarta Book of Quotations","author":"Swainson","year":"2000"},{"key":"2023012011495749600_ofac706-B5","volume-title":"The Sulfonamides and Allied Compounds","author":"Northey","year":"1948"},{"key":"2023012011495749600_ofac706-B6","volume-title":"YOUNG ROOSEVELT SAVED BY NEW DRUG; Doctor Used Prontylin in Fight on Streptococcus Infection of the Throat. CONDITION ONCE SERIOUS But Youth, in Boston Hospital, Gains Steadily \u2013 Fiancee, Reassured, Leaves Bedside. YOUNG ROOSEVELT SAVED BY NEW DRUG"},{"key":"2023012011495749600_ofac706-B7","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/bmj.2.4014.1156","article-title":"Sulphanilamide in the treatment of erysipelas","volume":"2","author":"Snodgrass","year":"1937","journal-title":"Br Med J"},{"key":"2023012011495749600_ofac706-B8","volume-title":"The Youngest Science. Notes of a Medicine-Watcher","author":"Thomas","year":"1983"},{"key":"2023012011495749600_ofac706-B9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7326\/0003-4819-149-2-200807150-00009","article-title":"The first use of penicillin in the United States","volume":"149","author":"Grossman","year":"2008","journal-title":"Ann Intern Med"},{"key":"2023012011495749600_ofac706-B10","first-page":"302","article-title":"Social ramifications of control of microbial disease","volume":"151","author":"McDermott","year":"1982","journal-title":"Johns Hopkins Med J"},{"key":"2023012011495749600_ofac706-B11","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.08.007","article-title":"Shorter antibiotic courses in the immunocompromised: the impossible dream?","author":"Imlay","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023012011495749600_ofac706-B12","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamainternmed.2016.3646","article-title":"The new antibiotic mantra-\u201cshorter is better\u201d","volume":"176","author":"Spellberg","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2023012011495749600_ofac706-B13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/M19-1509","article-title":"Duration of antibiotic therapy: shorter is better","volume":"171","author":"Spellberg","year":"2019","journal-title":"Ann Intern Med"},{"key":"2023012011495749600_ofac706-B14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.04.005","article-title":"The shorter is better movement: past, present, future","author":"Spellberg","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023012011495749600_ofac706-B15","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/cid\/ciy1134","article-title":"Short course antibiotic therapy-replacing Constantine units with \u201cshorter is better\u201d","volume":"69","author":"Wald-Dickler","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/526535","article-title":"The Maxwell Finland lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile","volume":"46","author":"Rice","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.07.025","article-title":"How to change the course: practical aspects of implementing shorter is better","author":"Dominguez","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023012011495749600_ofac706-B18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.7326\/M20-7355","article-title":"Appropriate use of short-course antibiotics in common infections: best practice advice from the American college of physicians","volume":"174","author":"Lee","year":"2021","journal-title":"Ann Intern Med"},{"key":"2023012011495749600_ofac706-B19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.08.024","article-title":"Short course antibiotics for common infections: what do we know and where do we go from here?","author":"Lee","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023012011495749600_ofac706-B20","author":"Fleming"},{"key":"2023012011495749600_ofac706-B21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.cmi.2021.10.022","article-title":"Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis","volume":"28","author":"Curran","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023012011495749600_ofac706-B22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/phar.2201","article-title":"Duration of exposure to antipseudomonal beta-lactam antibiotics in the critically ill and development of new resistance","volume":"39","author":"Teshome","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2023012011495749600_ofac706-B23","doi-asserted-by":"crossref","first-page":"c2096","DOI":"10.1136\/bmj.c2096","article-title":"Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis","volume":"340","author":"Costelloe","year":"2010","journal-title":"BMJ"},{"key":"2023012011495749600_ofac706-B24","article-title":"The antibiotic course has had its day","volume":"358","author":"Llewelyn","year":"2017","journal-title":"BMJ"},{"key":"2023012011495749600_ofac706-B25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1056\/NEJM197001222820406","article-title":"Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects","volume":"282","author":"Waldvogel","year":"1970","journal-title":"N Engl J Med"},{"key":"2023012011495749600_ofac706-B26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/cir842","article-title":"Systemic antibiotic therapy for chronic osteomyelitis in adults","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7326\/0003-4819-19-5-787","article-title":"Treatment of subacute bacterial endocarditis: current results","volume":"19","author":"Lichtman","year":"1943","journal-title":"Ann Intern Med"},{"key":"2023012011495749600_ofac706-B28","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jama.1942.02830230012003","article-title":"Subacute bacterial endocarditis due to Streptococcus viridans: survey of present status of previously reported cures and clinical study of fifteen treated cases, including another cure","volume":"119","author":"Smith","year":"1942","journal-title":"JAMA"},{"key":"2023012011495749600_ofac706-B29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7326\/0003-4819-22-1-75","article-title":"Observations on the treatment of subacute bacterial (streptococcal) endocarditis since 1939","volume":"22","author":"Kelson","year":"1945","journal-title":"Ann Intern Med"},{"key":"2023012011495749600_ofac706-B30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamainternmed.2020.0555","article-title":"Evaluation of a paradigm shift from intravenous antibiotics to oral step-down therapy for the treatment of infective endocarditis: a narrative review","volume":"180","author":"Spellberg","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2023012011495749600_ofac706-B31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1056\/NEJM195403042500906","article-title":"Treatment of bacterial endocarditis","volume":"250","author":"Finland","year":"1954","journal-title":"N Engl J Med"},{"key":"2023012011495749600_ofac706-B32","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","author":"Dunbar","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"2023012011495749600_ofac706-B33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diagmicrobio.2013.11.008","article-title":"A randomized controlled clinical trial of levofloxacin 750\u2005mg versus 500\u2005mg intravenous infusion in the treatment of community-acquired pneumonia","volume":"80","author":"Zhao","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023012011495749600_ofac706-B34","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0140-6736(02)09994-4","article-title":"Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial","volume":"360","author":"Pakistan Multicentre Amoxycillin Short Course Therapy Pneumonia Study Group","year":"2002","journal-title":"Lancet"},{"key":"2023012011495749600_ofac706-B35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/INF.0000000000000023","article-title":"Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial","volume":"33","author":"Greenberg","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2023012011495749600_ofac706-B36","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.332.7554.1355","article-title":"Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study","volume":"332","author":"el Moussaoui","year":"2006","journal-title":"BMJ"},{"key":"2023012011495749600_ofac706-B37","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial","volume":"176","author":"Uranga","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2023012011495749600_ofac706-B38","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy047","article-title":"Honey, I shrunk the antibiotic therapy","volume":"66","author":"Dinh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00006454-199810000-00004","article-title":"Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children","volume":"17","author":"Harris","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"2023012011495749600_ofac706-B40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1912400","article-title":"Amoxicillin for 3 or 5 days for chest-indrawing pneumonia in Malawian children","volume":"383","author":"Ginsburg","year":"2020","journal-title":"N Engl J Med"},{"key":"2023012011495749600_ofac706-B41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamapediatrics.2020.6735","article-title":"Short-course antimicrobial therapy for pediatric community-acquired pneumonia: the SAFER randomized clinical trial","volume":"175","author":"Pernica","year":"2021","journal-title":"JAMA Pediatr"},{"key":"2023012011495749600_ofac706-B42","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(21)00313-5","article-title":"Discontinuing beta-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial","volume":"397","author":"Dinh","year":"2021","journal-title":"Lancet"},{"key":"2023012011495749600_ofac706-B43","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1001\/jama.2021.17843","article-title":"Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: the CAP-IT randomized clinical trial","volume":"326","author":"Bielicki","year":"2021","journal-title":"JAMA"},{"key":"2023012011495749600_ofac706-B44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamapediatrics.2021.5547","article-title":"Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial","volume":"176","author":"Williams","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2023012011495749600_ofac706-B45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/INF.0000000000003558","article-title":"Extended versus standard antibiotic course duration in children &lt;5 years of age hospitalized with community-acquired pneumonia in high-risk settings: four-week outcomes of a multicenter, double-blind, parallel, superiority randomized controlled trial","volume":"41","author":"McCallum","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"2023012011495749600_ofac706-B46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02561528","article-title":"Azithromycin: single 1.5\u2005g dose in the treatment of patients with atypical pneumonia syndrome\u2013a randomized study","volume":"27","author":"Schonwald","year":"1999","journal-title":"Infection"},{"key":"2023012011495749600_ofac706-B47","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1164\/ajrccm.162.2.9909095","article-title":"Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription","volume":"162","author":"Singh","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2023012011495749600_ofac706-B48","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"2023012011495749600_ofac706-B49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041290","article-title":"Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment","volume":"7","author":"Capellier","year":"2012","journal-title":"PLoS One"},{"key":"2023012011495749600_ofac706-B50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1988.tb15899.x","article-title":"One or three weeks\u2019 treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam","volume":"223","author":"Jernelius","year":"1988","journal-title":"Acta Med Scand"},{"key":"2023012011495749600_ofac706-B51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0924-8579(95)00011-V","article-title":"A sequential study of intravenous and oral fleroxacin for 7 or 14 days in the treatment of complicated urinary tract infections","volume":"6","author":"de Gier","year":"1995","journal-title":"Int J Antimicrob Agents"},{"key":"2023012011495749600_ofac706-B52","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"2023012011495749600_ofac706-B53","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","author":"Sandberg","year":"2012","journal-title":"Lancet"},{"key":"2023012011495749600_ofac706-B54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750\u2005mg once-daily for five days with ciprofloxacin 400\/500\u2005mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"2023012011495749600_ofac706-B55","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1185\/030079907X233340","article-title":"A trial of levofloxacin 750\u2005mg once daily for 5 days versus ciprofloxacin 400\u2005mg and\/or 500\u2005mg twice daily for 10 days in the treatment of acute pyelonephritis","volume":"23","author":"Klausner","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2023012011495749600_ofac706-B56","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10096-017-2951-6","article-title":"Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial","volume":"36","author":"Dinh","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023012011495749600_ofac706-B57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12916-017-0835-3","article-title":"Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women","volume":"15","author":"van Nieuwkoop","year":"2017","journal-title":"BMC Med"},{"key":"2023012011495749600_ofac706-B58","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jama.2021.9899","article-title":"Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a randomized clinical trial","volume":"326","author":"Drekonja","year":"2021","journal-title":"JAMA"},{"key":"2023012011495749600_ofac706-B59","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","article-title":"Trial of short-course antimicrobial therapy for intraabdominal infection","volume":"372","author":"Sawyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2023012011495749600_ofac706-B60","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00134-018-5088-x","article-title":"Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial","volume":"44","author":"Montravers","year":"2018","journal-title":"Intensive Care Med"},{"key":"2023012011495749600_ofac706-B61","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B62","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"2023012011495749600_ofac706-B63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","article-title":"Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by enterobacterales: a randomized, controlled trial","volume":"28","author":"Molina","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023012011495749600_ofac706-B64","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/archinte.164.15.1669","article-title":"Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis","volume":"164","author":"Hepburn","year":"2004","journal-title":"Arch Intern Med"},{"key":"2023012011495749600_ofac706-B65","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"2023012011495749600_ofac706-B66","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2023012011495749600_ofac706-B67","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cmi.2019.09.019","article-title":"Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"26","author":"Cranendonk","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023012011495749600_ofac706-B68","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2337\/dc14-1514","article-title":"Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study","volume":"38","author":"Tone","year":"2015","journal-title":"Diabetes Care"},{"key":"2023012011495749600_ofac706-B69","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","article-title":"Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial","volume":"385","author":"Bernard","year":"2015","journal-title":"Lancet"},{"key":"2023012011495749600_ofac706-B70","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1093\/jac\/dkz202","article-title":"Four versus six weeks of antibiotic therapy for osteoarticular infections after implant removal: a randomized trial","volume":"74","author":"Benkabouche","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023012011495749600_ofac706-B71","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc13-1526","article-title":"Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial","volume":"37","author":"Lazaro-Martinez","year":"2014","journal-title":"Diabetes Care"},{"key":"2023012011495749600_ofac706-B72","doi-asserted-by":"crossref","first-page":"e1539","DOI":"10.1093\/cid\/ciaa1758","article-title":"Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: a prospective, randomized, non-inferiority pilot trial","volume":"73","author":"Gariani","year":"2021","journal-title":"Clin Infect Dis"},{"issue":":","key":"2023012011495749600_ofac706-B73","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2019-215116","article-title":"Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial","volume":"78","author":"Gjika","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023012011495749600_ofac706-B74","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/thx.2007.090613","article-title":"Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies","volume":"63","author":"Moussaoui R","year":"2008","journal-title":"Thorax"},{"key":"2023012011495749600_ofac706-B75","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221099729","article-title":"Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial","volume":"16","author":"Messous","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"2023012011495749600_ofac706-B76","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1128\/AAC.47.9.2770-2774.2003","article-title":"Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis","volume":"47","author":"Henry","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2023012011495749600_ofac706-B77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mhn.2002.126593","article-title":"Short treatment durations for acute bacterial rhinosinusitis: five days of gemifloxacin versus 7 days of gemifloxacin","volume":"127","author":"Ferguson","year":"2002","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2023012011495749600_ofac706-B78","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0149-2918(02)85023-8","article-title":"A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin\/clavulanate in patients with acute bacterial sinusitis","volume":"24","author":"Sher","year":"2002","journal-title":"Clin Ther"},{"key":"2023012011495749600_ofac706-B79","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000057670","article-title":"Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis","volume":"48","author":"Roos","year":"2002","journal-title":"Chemotherapy"},{"key":"2023012011495749600_ofac706-B80","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jama.1995.03520370057037","article-title":"Randomized controlled trial of 3 vs 10 days of trimethoprim\/sulfamethoxazole for acute maxillary sinusitis","volume":"273","author":"Williams","year":"1995","journal-title":"JAMA"},{"key":"2023012011495749600_ofac706-B81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0196-0709(99)90044-3","article-title":"Azithromycin versus amoxicillin\/clavulanate in the treatment of acute sinusitis","volume":"20","author":"Klapan","year":"1999","journal-title":"Am J Otolaryngol"},{"key":"2023012011495749600_ofac706-B82","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol"},{"key":"2023012011495749600_ofac706-B83","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/S2352-3026(22)00145-4","article-title":"Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial","volume":"9","author":"de Jonge","year":"2022","journal-title":"Lancet Haematol"},{"key":"2023012011495749600_ofac706-B84","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1473-3099(20)30084-0","article-title":"Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis","volume":"20","author":"de Jonge","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023012011495749600_ofac706-B85","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/lt.25486","article-title":"Intraoperative versus extended antibiotic prophylaxis in liver transplant surgery: a randomized controlled pilot trial","volume":"25","author":"Berry","year":"2019","journal-title":"Liver Transpl"},{"key":"2023012011495749600_ofac706-B86","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamaoncol.2021.6628","article-title":"Comparison of prophylactic intravenous antibiotic regimens after endoprosthetic reconstruction for lower extremity bone tumors: a randomized clinical trial","volume":"8","author":"Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Investigators","year":"2022","journal-title":"JAMA Oncol"},{"key":"2023012011495749600_ofac706-B87","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.6095","article-title":"Effect of antimicrobial prophylaxis duration on health care-associated infections after clean orthopedic surgery: a cluster randomized trial","volume":"5","author":"Nagata","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023012011495749600_ofac706-B88","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31583","article-title":"Effectiveness of single vs multiple doses of prophylactic intravenous antibiotics in implant-based breast reconstruction: a randomized clinical trial","volume":"5","author":"Gahm","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023012011495749600_ofac706-B89","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","article-title":"Short-course primaquine for the radical cure of plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial","volume":"394","author":"Taylor","year":"2019","journal-title":"Lancet"},{"key":"2023012011495749600_ofac706-B90","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00528-X","article-title":"Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial","author":"Stupica","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023012011495749600_ofac706-B91","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/jac\/dkx528","article-title":"Are infection specialists recommending short antibiotic treatment durations? An ESCMID international cross-sectional survey","volume":"73","author":"Macheda","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023012011495749600_ofac706-B92","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/cid\/ciab159","article-title":"Shorter and longer courses of antibiotics for common infections and the association with reductions of infection-related complications including hospital admissions","volume":"73","author":"Palin","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B93","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/jac\/dkac237","article-title":"Current clinical practice in antibiotic treatment of Staphylococcus aureus bacteraemia: results from a survey in five European countries","volume":"77","author":"Buis","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023012011495749600_ofac706-B94","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac005","article-title":"Survey of infectious diseases providers reveals variability in duration of antibiotic therapy for the treatment of gram-negative bloodstream infections","volume":"4","author":"Thaden","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2023012011495749600_ofac706-B95","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7326\/M18-3640","article-title":"Excess antibiotic duration and adverse-1 events in patients hospitalized with pneumonia: a multi-hospital cohort study","volume":"171","author":"Vaughn","year":"2019","journal-title":"Ann Intern Med"},{"key":"2023012011495749600_ofac706-B96","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/cid\/ciz713","article-title":"Late-career physicians prescribe longer courses of antibiotics","volume":"70","author":"Fernandez-Lazaro","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B97","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa2020198","article-title":"Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection","volume":"384","author":"Bernard","year":"2021","journal-title":"N Engl J Med"},{"key":"2023012011495749600_ofac706-B98","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1056\/NEJMoa1606043","article-title":"Shortened antimicrobial treatment for acute otitis media in young children","volume":"375","author":"Hoberman","year":"2016","journal-title":"N Engl J Med"},{"key":"2023012011495749600_ofac706-B99","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S1473-3099(22)00057-3","article-title":"Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India","volume":"22","author":"Sehgal","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023012011495749600_ofac706-B100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053039","article-title":"Low-dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial","volume":"12","author":"Sohani","year":"2022","journal-title":"BMJ Open"},{"key":"2023012011495749600_ofac706-B101","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.amjmed.2021.10.007","article-title":"Oral is the new IV\u2013challenging decades of blood and bone infection dogma: a systematic review","volume":"135","author":"Wald-Dickler","year":"2021","journal-title":"Am J Med"},{"key":"2023012011495749600_ofac706-B102","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.11321","article-title":"Use of novel strategies to develop guidelines for management of pyogenic osteomyelitis in adults: a WikiGuidelines group consensus statement","volume":"5","author":"Spellberg","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023012011495749600_ofac706-B103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106598","article-title":"Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome ranking (DOOR) endpoint","volume":"60","author":"Manning","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2023012011495749600_ofac706-B104","first-page":"266","article-title":"Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis","volume":"82","author":"Greenberg","year":"1987","journal-title":"Am J Med"},{"key":"2023012011495749600_ofac706-B105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2106\/00004623-199072010-00017","article-title":"Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults","volume":"72","author":"Mader","year":"1990","journal-title":"J Bone Joint Surg Am"},{"key":"2023012011495749600_ofac706-B106","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/AAC.34.1.40","article-title":"Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis","volume":"34","author":"Gentry","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"2023012011495749600_ofac706-B107","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/AAC.35.3.538","article-title":"Ofloxacin versus parenteral therapy for chronic osteomyelitis","volume":"35","author":"Gentry","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2023012011495749600_ofac706-B108","first-page":"244","article-title":"Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis","volume":"12","author":"Gomis","year":"1999","journal-title":"Rev Esp Quimioter"},{"key":"2023012011495749600_ofac706-B109","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/424506","article-title":"A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection","volume":"39","author":"Schrenzel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B110","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1128\/AAC.01504-08","article-title":"Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis","volume":"53","author":"Euba","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023012011495749600_ofac706-B111","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2023012011495749600_ofac706-B112","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/0036554021000026933","article-title":"Linezolid community-acquired pneumonia study G. Linezolid versus ceftriaxone\/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia","volume":"34","author":"Pedro GS","year":"2002","journal-title":"Scand J Infect Dis"},{"issue":"9 Suppl","key":"2023012011495749600_ofac706-B113","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/01.inf.0000086955.93702.c7","article-title":"Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates","volume":"22","author":"Deville","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"9 Suppl","key":"2023012011495749600_ofac706-B114","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1097\/01.inf.0000086956.45566.55","article-title":"Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens","volume":"22","author":"Jantausch","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2023012011495749600_ofac706-B115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.inf.0000078160.29072.42","article-title":"Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2023012011495749600_ofac706-B116","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jac\/dkh088","article-title":"Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections","volume":"53","author":"Wilcox","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2023012011495749600_ofac706-B117","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B118","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/106002809603000605","article-title":"Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis","volume":"30","author":"Amodio-Groton","year":"1996","journal-title":"Ann Pharmacother"},{"key":"2023012011495749600_ofac706-B119","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1016\/j.ijid.2012.07.009","article-title":"A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400\u2005mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis","volume":"16","author":"Monmaturapoj","year":"2012","journal-title":"Int J Infect Dis"},{"key":"2023012011495749600_ofac706-B120","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1007\/s10620-014-3233-0","article-title":"Early oral antibiotic switch compared with conventional intravenous antibiotic therapy for acute cholangitis with bacteremia","volume":"59","author":"Park","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"Suppl 2","key":"2023012011495749600_ofac706-B121","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1093\/clinids\/13.Supplement_2.S160","article-title":"Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci","volume":"13","author":"Stamboulian","year":"1991","journal-title":"Rev Infect Dis"},{"key":"2023012011495749600_ofac706-B122","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9343(96)00070-8","article-title":"Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy","volume":"101","author":"Heldman","year":"1996","journal-title":"Am J Med"},{"key":"2023012011495749600_ofac706-B123","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJMc1902096","article-title":"Long-term outcomes of partial oral treatment of endocarditis","volume":"380","author":"Bundgaard","year":"2019","journal-title":"N Engl J Med"},{"key":"2023012011495749600_ofac706-B124","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/clind\/24.4.643","article-title":"Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens","volume":"24","author":"Lipsky","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1086\/380449","article-title":"Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam\/amoxicillin-clavulanate","volume":"38","author":"Lipsky","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B126","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijantimicag.2016.05.021","article-title":"Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial","volume":"48","author":"Lora-Tamayo","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2023012011495749600_ofac706-B127","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1469-0691.2011.03643.x","article-title":"Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood\u2013a prospective quasi-randomized controlled trial","volume":"18","author":"Peltola","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2023012011495749600_ofac706-B128","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1086\/522534","article-title":"Adjuvant glycerol and\/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial","volume":"45","author":"Peltola","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B129","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1542\/peds.99.6.846","article-title":"Simplified treatment of acute staphylococcal osteomyelitis of childhood. The Finnish study group","volume":"99","author":"Peltola","year":"1997","journal-title":"Pediatrics"},{"key":"2023012011495749600_ofac706-B130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1201-9712(01)90041-4","article-title":"Successful shortening from seven to four days of parenteral beta-lactam treatment for common childhood infections: a prospective and randomized study","volume":"5","author":"Peltola","year":"2001","journal-title":"Int J Infect Dis"},{"key":"2023012011495749600_ofac706-B131","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01241398-200205000-00009","article-title":"Short-term intravenous antibiotic treatment of acute hematogenous bone and joint infection in children: a prospective randomized trial","volume":"22","author":"Jaberi","year":"2002","journal-title":"J Pediatr Orthop"},{"key":"2023012011495749600_ofac706-B132","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/bmj.38993.560984.BE","article-title":"Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial","volume":"333","author":"Oosterheert","year":"2006","journal-title":"BMJ"},{"key":"2023012011495749600_ofac706-B133","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/apa.14373","article-title":"Outpatients with acute osteoarticular infections had favourable outcomes when they received just oral antibiotics without intravenous antibiotics","volume":"107","author":"Alcobendas","year":"2018","journal-title":"Acta Paediatr"},{"key":"2023012011495749600_ofac706-B134","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/INF.0000000000002790","article-title":"Daptomycin for pediatric Gram-positive acute hematogenous osteomyelitis","volume":"39","author":"Bradley","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2023012011495749600_ofac706-B135","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/INF.0b013e3181f55a89","article-title":"Short- versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases","volume":"29","author":"Peltola","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"2023012011495749600_ofac706-B136","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz386","article-title":"Practice patterns of infectious diseases physicians in transitioning from intravenous to oral therapy in patients with bacteremia","volume":"7","author":"Hospenthal","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023012011495749600_ofac706-B137","first-page":"507","article-title":"The medical reputation of Benjamin Rush: contrasts over two centuries","volume":"45","author":"Shryock","year":"1971","journal-title":"Bull Hist Med"},{"key":"2023012011495749600_ofac706-B138","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: understanding time lags in translational research","volume":"104","author":"Morris","year":"2011","journal-title":"J R Soc Med"},{"key":"2023012011495749600_ofac706-B139","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/cid\/cix1127","article-title":"Busting the myth of \u201cstatic vs. cidal\u201d: a systemic literature review","volume":"66","author":"Wald-Dickler","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023012011495749600_ofac706-B140","first-page":"2418","article-title":"Comparison of mono- and combination antibiotic therapy for the treatment of Pseudomonas aeruginosa bacteraemia: a cumulative meta-analysis of cohort studies","volume":"15","author":"Tang","year":"2018","journal-title":"Exp Ther Med"},{"key":"2023012011495749600_ofac706-B141","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijantimicag.2013.09.002","article-title":"Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies","volume":"42","author":"Hu","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2023012011495749600_ofac706-B142","article-title":"Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis","volume":"2014","author":"Paul","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2023012011495749600_ofac706-B143","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1001\/jama.2012.5833","article-title":"Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial","volume":"307","author":"Brunkhorst","year":"2012","journal-title":"JAMA"},{"key":"2023012011495749600_ofac706-B144","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijantimicag.2012.12.006","article-title":"beta-lactam plus aminoglycoside or fluoroquinolone combination versus beta-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis","volume":"41","author":"Vardakas","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2023012011495749600_ofac706-B145","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab624","article-title":"Safety and efficacy of antibiotic de-escalation and discontinuation in high-risk hematological patients with febrile neutropenia: a single-center experience","volume":"9","author":"Verlinden","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023012011495749600_ofac706-B146","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkl044","article-title":"The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials","volume":"57","author":"Falagas","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2023012011495749600_ofac706-B147","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"key":"2023012011495749600_ofac706-B148","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac583","article-title":"Deconstructing the dogma: systematic literature review and meta-analysis of adjunctive gentamicin and rifampin in staphylococcal prosthetic valve endocarditis","volume":"9","author":"Ryder","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023012011495749600_ofac706-B149","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/DCR.0000000000001324","article-title":"Antibiotics versus no antibiotics for acute uncomplicated diverticulitis: a systematic review and meta-analysis","volume":"62","author":"Desai","year":"2019","journal-title":"Dis Colon Rectum"},{"key":"2023012011495749600_ofac706-B150","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac645","article-title":"Revisiting the evidence base for modern day practice of the treatment of toxoplasmic encephalitis: a systematic review and meta-analysis","author":"Prosty","year":"2022","journal-title":"Clin Infect Dis"},{"issue":":","key":"2023012011495749600_ofac706-B151","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"25","author":"Weis","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2023012011495749600_ofac706-B152","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2019.0733","article-title":"Utility of ophthalmologic screening for patients with Candida bloodstream infections: a systematic review","volume":"137","author":"Breazzano","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"2023012011495749600_ofac706-B153","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/CIA.S183344","article-title":"Antibacterial treatment of aspiration pneumonia in older people: a systematic review","volume":"13","author":"Bowerman","year":"2018","journal-title":"Clin Interv Aging"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac706\/48445287\/ofac706.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/1\/ofac706\/48798120\/ofac706.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/1\/ofac706\/48798120\/ofac706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T11:51:27Z","timestamp":1674215487000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac706\/6965273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":153,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac706","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,12,29]]},"article-number":"ofac706"}}